AbbVie Inc.
AbbVie Inc. Announces Issuance of Senior Notes
Summary
On February 18, 2025, AbbVie Inc. entered into an underwriting agreement to issue and sell $1,250,000,000 in aggregate principal amount of its 4.650% senior notes due 2028, $1,000,000,000 in aggregate principal amount of its 4.875% senior notes due 2030, $1,000,000,000 in aggregate principal amount of its 5.2000% senior notes due 2035, and $750,000,000 in aggregate principal amount of its 5.600% senior notes due 2055. The net proceeds from the sale of the Notes are expected to be approximately $3.98 billion, which AbbVie intends to use to repurchase or redeem certain of its existing senior notes and for general corporate purposes.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement